cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Moleculin Biotech Inc
22 own
26 watching
Current Price
$0
$0
(0.4%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
35.78M
52-Week High
52-Week High
2.05
52-Week Low
52-Week Low
0.817
Average Volume
Average Volume
0.01M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization35.78M
icon52-Week High2.05
icon52-Week Low0.817
iconAverage Volume0.01M
iconDividend Yield--
iconP/E Ratio--
What does the Moleculin Biotech Inc do?
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company s flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company has partnership and collaboration agreements with MD Anderson; Animal Life Sciences, LLC; and WPD Pharmaceuticals Sp z.o.o. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.
Read More
How much money does Moleculin Biotech Inc make?
News & Events about Moleculin Biotech Inc.
Accesswire
28days ago
- Live video webcast presentations with participating companies -FRENCHTOWN, NJ / ACCESSWIRE / January 11, 2023 / JTC Team ('JTC'), a fully integrated corporate communications and investor relations firm, today announced it will host the Virtual Investor 2023 Companies to Watch Event...
Ticker Report
1month ago
StockNews.com began coverage on shares of Moleculin Biotech (NASDAQ:MBRX Get Rating) in a research report released on Thursday morning. The brokerage issued a sell rating on the stock. Separately, Oppenheimer dropped their price target on shares of Moleculin Biotech from $14.00 to $5.00 in a...
PR Newswire
1month ago
Moleculin Receives Approval in Italy to Conduct Phase 1/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML) Moleculin Receives Approval in Italy to Conduct Phase 1/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C...
PR Newswire
2 months ago
Moleculin Granted FDA Fast Track Designation of WP1122 for the Treatment of Glioblastoma Multiforme Moleculin Granted FDA Fast Track Designation of WP1122 for the Treatment of Glioblastoma Multiforme PR Newswire HOUSTON, Dec. 7, 2022 HOUSTON, Dec. 7, 2022 /PRNewswire/ -- Moleculin Biotech, Inc...
Ticker Report
2 months ago
StockNews.com started coverage on shares of Moleculin Biotech (NASDAQ:MBRX Get Rating) in a research report sent to investors on Sunday morning. The brokerage issued a sell rating on the stock. A number of other research firms also recently weighed in on MBRX. Oppenheimer decreased their ...
Frequently Asked Questions
Frequently Asked Questions
What is Moleculin Biotech Inc share price today?
plus_minus_icon
Can Indians buy Moleculin Biotech Inc shares?
plus_minus_icon
How can I buy Moleculin Biotech Inc shares from India?
plus_minus_icon
Can Fractional shares of Moleculin Biotech Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Moleculin Biotech Inc stocks?
plus_minus_icon
What is today’s traded volume of Moleculin Biotech Inc?
plus_minus_icon
What is today’s market capitalisation of Moleculin Biotech Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Moleculin Biotech Inc?
plus_minus_icon
What percentage is Moleculin Biotech Inc down from its 52-Week High?
plus_minus_icon
What percentage is Moleculin Biotech Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$0
(0.4%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
MEDAVAIL HOLDINGS INC
MEDAVAIL HOLDINGS INC
$0.37
$-0.02 (-4.29 %)
Applied Therapeutics Inc
Applied Therapeutics Inc
$1.08
$-0.05 (-4.02 %)
Humanigen Inc
Humanigen Inc
$0.23
$0.00 (0.53 %)
I-Mab
I-Mab
$5.07
$0.05 (1.00 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
MEDAVAIL HOLDINGS INC
MEDAVAIL HOLDINGS INC
$0.37
$-0.02 (-4.29 %)
Applied Therapeutics Inc
Applied Therapeutics Inc
$1.08
$-0.05 (-4.02 %)
Humanigen Inc
Humanigen Inc
$0.23
$0.00 (0.53 %)
I-Mab
I-Mab
$5.07
$0.05 (1.00 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00